Citadel Advisors »

Arrivent Biopharma shares owned by Citadel Advisors

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $9.2M 459k 20.12
2025-06-30 $733k 34k 21.77
2024-03-31 $5.1M 287k 17.86

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Amazon Call Option (AMZN)
Spdr Gold Tr Gold Shs Call Option (GLD)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Microsoft Corporation Call Option (MSFT)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Broadcom Call Option (AVGO)
Netflix Call Option (NFLX)
Alphabet Cap Stk Cl C Call Option (GOOG)
Advanced Micro Devices Call Option (AMD)

View all positions for Citadel Advisors

Top funds holding Arrivent Biopharma

Infinitum Asset Management
Suvretta Capital Management
Hillhouse Capital Advisors
FMR
OrbiMed Advisors
BlackRock
Octagon Capital Advisors
Novo A/S
Vanguard Group
Sofinnova Ventures
Vanguard Capital Management
General Catalyst Group Management
State Street Corporation
Geode Capital Management
Goldman Sachs Group

View all funds holding Arrivent Biopharma